Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company based in Research Triangle Park, North Carolina, is preparing to announce its financial results for the full year and fourth quarter of 2024. This announcement is set to occur before the U.S. markets open on March 10, 2025. In conjunction with the financial report, Fennec will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day, during which management will discuss the company’s performance and business developments.

Fennec specializes in the development and commercialization of PEDMARK®, a medication designed to mitigate the risk of platinum-induced ototoxicity in pediatric patients. PEDMARK received FDA approval in September 2022, followed by European Commission approval in June 2023, and U.K. approval in October 2023 under the name PEDMARQSI. The drug holds significant regulatory endorsements, such as Orphan Drug Exclusivity in the U.S. and Pediatric Use Marketing Authorization in Europe, providing it with a protected status for up to ten years in the latter market.

Investors and stakeholders interested in tuning into the conference call can access the live event through Fennec's website, where they are advised to log on at least 15 minutes prior to ensure readiness for any necessary software downloads. A replay of the call will be available for thirty days following the event.

As Fennec Pharmaceuticals continues to advance its commitment to pediatric healthcare through innovative pharmaceutical solutions, the upcoming financial results and consequent discussion are poised to provide valuable insights into the company's ongoing growth and strategic direction. For further inquiries, potential investors and media representatives can reach out to the company's dedicated contacts.

As Fennec Pharmaceuticals Inc. prepares to release its full year and fourth quarter financial results for 2024 on March 10, 2025, investors should closely analyze the implications of this report for the company's future performance and stock trajectory. With the FDA's approval of its lead product, PEDMARK®, to reduce platinum-induced ototoxicity in pediatric patients, Fennec has positioned itself strategically within a niche market, backed by both U.S. and European regulatory approvals.

Investors should pay particular attention to the sales figures for PEDMARK in the upcoming earnings call. Since receiving FDA approval in September 2022, the company has had time to establish its presence in the marketplace. The revenue generated thus far, particularly from pediatric hospitals and oncology units, will be crucial in assessing the product's market penetration and future growth potential. It will also be essential to evaluate any updates regarding partnerships, distribution agreements, or new initiatives that could expand PEDMARK's reach.

Furthermore, the financial implications of Fennec's orphan drug exclusivity and data protection in Europe should not be underestimated; these factors can significantly enhance long-term revenue visibility. Market analysts should scrutinize Fennec’s operational costs and investment in R&D, as these will directly affect margin growth and profitability projections.

Lastly, this earnings report and subsequent conference call will serve as a pivotal moment for Fennec's stock performance. If results meet or exceed expectations, they can positively influence investor sentiment, potentially driving share prices upwards. Conversely, disappointing growth metrics could pose risks for current and prospective investors. Thus, it is advisable to remain alert to both the numerical results and qualitative insights from management's discussion during the call.